Satya P. Kunapuli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Satya P. Kunapuli has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Jianguo Jin
5 shared publicationsCarol Dangelmaier
Department of Pharmacology, Temple University Medical School, Philadelphia, PA, USA
2 shared publications- Alexander Georgakis
Division of Cardiology, Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
1 shared publication Bryan J. Smith
Department of Pharmacology, Temple University Medical School, Philadelphia, PA, USA
1 shared publicationDavid Fiss
1 shared publicationIan P Kirk
22Discovery BioScience Department, AstraZeneca R&D Charnwood, Loughborough
1 shared publication
Latest Publications
- 1 July 2008
- Vol. 20 (7) , 349-53
Risk of thrombogenicity among nonionic radiocontrast agents.
Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.
- 1 July 2008
- Vol. 20 (7) , 349-53
Risk of thrombogenicity among nonionic radiocontrast agents.
Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.
- 1 April 2003
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 3 (2) , 175-180
Platelet purinergic receptors
- 1 April 2003
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 3 (2) , 175-180
Platelet purinergic receptors
- Open Access
- 1 January 2002
- Published by Wiley in The Scientific World Journal
- Vol. 2, 424-433
P2 Receptors and Platelet Activation
Adenosine diphosphate (ADP) plays a crucial role in hemostasis and thrombosis by activating platelets. In platelets, the classical P2T receptor is now resolved into three P2 receptor subtypes: the P2Y1, the P2Y12, and the P2X1 receptors. Both pharmacological and molecular biological approaches have confirmed the role of the P2Y1 and P2Y12 receptors in the ADP-induced platelet fibrinogen receptor activation. The P2Y1 and the P2X1 receptors independently contribute to platelet shape change. Whereas the P2Y12 receptor mediates the potentiation of dense granule release reaction, both the P2Y1 and P2Y12 receptors play an important role in the ADP-induced phospholipase A2 activation. The signaling events downstream of these receptors leading to the physiological effects remain elusive, and they are yet to be delineated.
- 1 January 2002
- Published by Wiley in The Scientific World Journal
- Vol. 2, 424-433
Open AccessP2 Receptors and Platelet Activation
Adenosine diphosphate (ADP) plays a crucial role in hemostasis and thrombosis by activating platelets. In platelets, the classical P2T receptor is now resolved into three P2 receptor subtypes: the P2Y1, the P2Y12, and the P2X1 receptors. Both pharmacological and molecular biological approaches have confirmed the role of the P2Y1 and P2Y12 receptors in the ADP-induced platelet fibrinogen receptor activation. The P2Y1 and the P2X1 receptors independently contribute to platelet shape change. Whereas the P2Y12 receptor mediates the potentiation of dense granule release reaction, both the P2Y1 and P2Y12 receptors play an important role in the ADP-induced phospholipase A2 activation. The signaling events downstream of these receptors leading to the physiological effects remain elusive, and they are yet to be delineated.
- 1 June 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (4) , 521-528
The C6‐2B glioma cell P2YAC receptor is pharmacologically and molecularly identical to the platelet P2Y12 receptor
P2Y receptor activation in many cell types leads to phospholipase C activation and accumulation of inositol phosphates, while in blood platelets, C6‐2B glioma cells, and in B10 microvascular endothelial cells a P2Y receptor subtype, which couples to inhibition of adenylyl cyclase, historically termed P2YAC, (P2TAC or P2T in platelets) has been identified. Recently, this receptor has been cloned and designated P2Y12 in keeping with current P2 receptor nomenclature. Three selective P2T receptor antagonists, with a range of affinities, inhibited ADP‐induced aggregation of washed human or rat platelets, in a concentration‐dependent manner, with a rank order of antagonist potency (pIC50, human: rat) of AR‐C78511 (8.5 : 9.1)>AR‐C69581 (6.2 : 6.0)>AR‐C70300 (5.4 : 5.1). However, these compounds had no effect on ADP‐induced platelet shape change. All three antagonists had no significant effect on the ADP‐induced inositol phosphate formation in 1321N1 astrocytoma cells stably expressing the P2Y1 receptor, when used at concentrations that inhibit platelet aggregation. These antagonists also blocked ADP‐induced inhibition of adenylyl cyclase in rat platelets and C6‐2B cells with identical rank orders of potency and overlapping concentration – response curves. RT – PCR and nucleotide sequence analyses revealed that the C6‐2B cells express the P2Y12 mRNA. These data demonstrate that the P2YAC receptor in C6‐2B cells is pharmacologically identical to the P2TAC receptor in rat platelets. British Journal of Pharmacology (2001) 133, 521–528; doi:10.1038/sj.bjp.0704114
- 1 June 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (4) , 521-528
The C6‐2B glioma cell P2YAC receptor is pharmacologically and molecularly identical to the platelet P2Y12 receptor
P2Y receptor activation in many cell types leads to phospholipase C activation and accumulation of inositol phosphates, while in blood platelets, C6‐2B glioma cells, and in B10 microvascular endothelial cells a P2Y receptor subtype, which couples to inhibition of adenylyl cyclase, historically termed P2YAC, (P2TAC or P2T in platelets) has been identified. Recently, this receptor has been cloned and designated P2Y12 in keeping with current P2 receptor nomenclature. Three selective P2T receptor antagonists, with a range of affinities, inhibited ADP‐induced aggregation of washed human or rat platelets, in a concentration‐dependent manner, with a rank order of antagonist potency (pIC50, human: rat) of AR‐C78511 (8.5 : 9.1)>AR‐C69581 (6.2 : 6.0)>AR‐C70300 (5.4 : 5.1). However, these compounds had no effect on ADP‐induced platelet shape change. All three antagonists had no significant effect on the ADP‐induced inositol phosphate formation in 1321N1 astrocytoma cells stably expressing the P2Y1 receptor, when used at concentrations that inhibit platelet aggregation. These antagonists also blocked ADP‐induced inhibition of adenylyl cyclase in rat platelets and C6‐2B cells with identical rank orders of potency and overlapping concentration – response curves. RT – PCR and nucleotide sequence analyses revealed that the C6‐2B cells express the P2Y12 mRNA. These data demonstrate that the P2YAC receptor in C6‐2B cells is pharmacologically identical to the P2TAC receptor in rat platelets. British Journal of Pharmacology (2001) 133, 521–528; doi:10.1038/sj.bjp.0704114
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 85 (02) , 341-348
Potentiation of Thromboxane A2-induced Platelet Secretion by Gi Signaling through the Phosphoinositide-3 Kinase Pathway
Platelet activation results in shape change, aggregation, generation of thromboxane A2, and release of granule contents. We have recently demonstrated that secreted ADP is essential for thromboxane A2-induced platelet aggregation (J. Biol. Chem. 274: 29108-29114, 1999). The aim of this study was to investigate the role of secreted ADP interacting at P2 receptor subtypes in platelet secretion. Platelet secretion induced by the thromboxane A2 mimetic U46619 was unaffected by adenosine-3’phosphate-5’-phosphate, a P2Y1 receptor selective antagonist. However, AR-C66096, a selective antagonist of the P2T AC receptor, inhibited U46619-induced platelet secretion, indicating an important role for Gi signaling in platelet secretion. Selective activation of either the P2T AC receptor or the α2A adrenergic receptor did not cause platelet secretion, but potentiated U46619-induced platelet secretion. SC57101, a fibrinogen receptor antagonist, failed to inhibit platelet secretion, demonstrating that outside-in signaling was not required for platelet secretion. Since Gi signaling results in reduction of basal cAMP levels through inhibition of adenylyl cyclase, we investigated whether this is the signaling event that potentiates platelet secretion. SQ22536 or dideoxyadenosine, inhibitors of adenylyl cyclase, failed to potentiate U46619-induced primary platelet secretion, indicating that reduction in cAMP levels does not directly contribute to platelet secretion. Wortmannin, a selective inhibitor of PI-3 kinase, minimally inhibited U46619-induced platelet secretion when it was solely mediated by Gq, but dramatically ablated the potentiation of Gi signaling. We conclude that signaling through the P2TAC receptor by secreted ADP causes positive feedback on platelet secretion through a PI-3 kinase pathway.
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 85 (02) , 341-348
Potentiation of Thromboxane A2-induced Platelet Secretion by Gi Signaling through the Phosphoinositide-3 Kinase Pathway
Platelet activation results in shape change, aggregation, generation of thromboxane A2, and release of granule contents. We have recently demonstrated that secreted ADP is essential for thromboxane A2-induced platelet aggregation (J. Biol. Chem. 274: 29108-29114, 1999). The aim of this study was to investigate the role of secreted ADP interacting at P2 receptor subtypes in platelet secretion. Platelet secretion induced by the thromboxane A2 mimetic U46619 was unaffected by adenosine-3’phosphate-5’-phosphate, a P2Y1 receptor selective antagonist. However, AR-C66096, a selective antagonist of the P2T AC receptor, inhibited U46619-induced platelet secretion, indicating an important role for Gi signaling in platelet secretion. Selective activation of either the P2T AC receptor or the α2A adrenergic receptor did not cause platelet secretion, but potentiated U46619-induced platelet secretion. SC57101, a fibrinogen receptor antagonist, failed to inhibit platelet secretion, demonstrating that outside-in signaling was not required for platelet secretion. Since Gi signaling results in reduction of basal cAMP levels through inhibition of adenylyl cyclase, we investigated whether this is the signaling event that potentiates platelet secretion. SQ22536 or dideoxyadenosine, inhibitors of adenylyl cyclase, failed to potentiate U46619-induced primary platelet secretion, indicating that reduction in cAMP levels does not directly contribute to platelet secretion. Wortmannin, a selective inhibitor of PI-3 kinase, minimally inhibited U46619-induced platelet secretion when it was solely mediated by Gq, but dramatically ablated the potentiation of Gi signaling. We conclude that signaling through the P2TAC receptor by secreted ADP causes positive feedback on platelet secretion through a PI-3 kinase pathway.
- 1 July 2000
- Published by Elsevier in Immunopharmacology
- Vol. 48 (2) , 157-163
Distribution of leukotriene B4 receptors in human hematopoietic cells
- 1 July 2000
- Published by Elsevier in Immunopharmacology
- Vol. 48 (2) , 157-163
Distribution of leukotriene B4 receptors in human hematopoietic cells
- Open Access
- 1 April 2000
- Published by Wiley in European Journal of Biochemistry
- Vol. 267 (8) , 2283-2289
The P2Y1 receptor mediates ADP‐induced p38 kinase‐activating factor generation in human platelets
U46619, a thromboxane A2 mimetic, but not ADP, caused activation of p38 mitogen activated protein (MAP) kinase in aspirin‐treated platelets. In nonaspirinated human platelets ADP activated p38 MAP kinase in both a time‐and concentration‐dependent manner, suggesting that ADP‐induced p38 MAP kinase activation requires generation of thromboxane A2. However, neither a thromboxane A2/prostaglandin H2 receptor antagonist SQ29548 and a thromboxane synthase inhibitor, furegrelate, either alone or together, nor indomethacin blocked ADP‐induced p38 kinase activation in nonaspirinated platelets. Other cycloxygenase products, PGE2, PGD2, and PGF2α, failed to activate p38 kinase in aspirin‐treated platelets. Hence, ADP must be generating an agonist, other than thromboxane A2, via an aspirin‐sensitive pathway, which is capable of activating p38 kinase. AR‐C66096, a P2TAC (platelet ADP receptor coupled to inhibition of adenylate cyclase) antagonist, did not inhibit ADP‐induced p38 MAP kinase activation. The P2X receptor selective agonist, α,β‐methylene ATP, failed to activate p38 MAP kinase. On the other hand, the P2Y1 receptor selective antagonist, adenosine‐2′‐phosphate‐5′‐phosphate inhibited ADP‐induced p38 kinase activation in a concentration‐dependent manner, indicating that the P2Y1 receptor alone mediates ADP‐induced generation of the p38 kinase‐activating factor. These results demonstrate that ADP causes the generation of a factor in human platelets, which can activate p38 kinase, and that this response is mediated by the P2Y1 receptor. Neither the P2TAC receptor nor the P2X1 receptor has any significant role in this response.
- 1 April 2000
- Published by Wiley in European Journal of Biochemistry
- Vol. 267 (8) , 2283-2289
Open AccessThe P2Y1 receptor mediates ADP‐induced p38 kinase‐activating factor generation in human platelets
U46619, a thromboxane A2 mimetic, but not ADP, caused activation of p38 mitogen activated protein (MAP) kinase in aspirin‐treated platelets. In nonaspirinated human platelets ADP activated p38 MAP kinase in both a time‐and concentration‐dependent manner, suggesting that ADP‐induced p38 MAP kinase activation requires generation of thromboxane A2. However, neither a thromboxane A2/prostaglandin H2 receptor antagonist SQ29548 and a thromboxane synthase inhibitor, furegrelate, either alone or together, nor indomethacin blocked ADP‐induced p38 kinase activation in nonaspirinated platelets. Other cycloxygenase products, PGE2, PGD2, and PGF2α, failed to activate p38 kinase in aspirin‐treated platelets. Hence, ADP must be generating an agonist, other than thromboxane A2, via an aspirin‐sensitive pathway, which is capable of activating p38 kinase. AR‐C66096, a P2TAC (platelet ADP receptor coupled to inhibition of adenylate cyclase) antagonist, did not inhibit ADP‐induced p38 MAP kinase activation. The P2X receptor selective agonist, α,β‐methylene ATP, failed to activate p38 MAP kinase. On the other hand, the P2Y1 receptor selective antagonist, adenosine‐2′‐phosphate‐5′‐phosphate inhibited ADP‐induced p38 kinase activation in a concentration‐dependent manner, indicating that the P2Y1 receptor alone mediates ADP‐induced generation of the p38 kinase‐activating factor. These results demonstrate that ADP causes the generation of a factor in human platelets, which can activate p38 kinase, and that this response is mediated by the P2Y1 receptor. Neither the P2TAC receptor nor the P2X1 receptor has any significant role in this response.